Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -5.4%. (2008–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $698952 | $562074 | $783328 | $2M | $2M | $3M | $4M | $4M | $5M | $5M | $7M |
| Enterprise Value | $491M | $3.3B | $3.7B | $3.2B | $3.1B | $2.6B | $2.0B | $1.5B | $539M | $1.1B | $1.0B |
| P/E Ratio → | -0.05 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.01 | 0.01 |
| P/B Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | 0.18 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.25 | 9.68 | 6.03 | 6.53 | 5.31 | 9.07 | 7.33 | 2.82 | 3.47 | 2.21 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 5.6% | 5.6% | -20.6% | -14.3% | -32.3% | -11.7% | 5.9% | -8.0% | 10.4% | 29.6% | 37.0% |
| Operating Margin | -52.0% | -52.0% | -138.6% | -86.2% | -111.2% | -94.4% | -141.7% | -220.5% | -156.8% | -64.0% | -37.1% |
| Net Profit Margin | -20.2% | -20.2% | -80.3% | -55.4% | -103.7% | -55.9% | -139.0% | -154.8% | -123.0% | -85.9% | -57.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.4% | -5.4% | -18.3% | -15.8% | -20.6% | -10.6% | -14.5% | -14.8% | -14.3% | -25.3% | -19.6% |
| ROA | -1.4% | -1.4% | -4.8% | -4.9% | -8.0% | -4.7% | -6.4% | -6.9% | -5.8% | -8.5% | -7.7% |
| ROIC | -3.4% | -3.4% | -7.7% | -6.9% | -7.6% | -7.1% | -6.1% | -10.7% | -9.0% | -7.2% | -5.4% |
| ROCE | -5.2% | -5.2% | -12.2% | -10.3% | -10.2% | -8.9% | -7.4% | -11.8% | -9.9% | -9.1% | -7.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.96 | 1.96 | 2.43 | 1.89 | 1.61 | 1.00 | 0.98 | 0.81 | 0.41 | 1.22 | 0.97 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 1.80 | 2.30 | 1.85 | 1.53 | 0.94 | 0.84 | 0.77 | 0.23 | 1.13 | 0.81 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.45 | -1.45 | -2.47 | -2.79 | -4.36 | -6.21 | -3.78 | -12.59 | -6.36 | -2.04 | -1.20 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.48 | 0.48 | 0.46 | 0.32 | 0.68 | 0.73 | 1.32 | 0.45 | 1.41 | 1.00 | 1.26 |
| Quick Ratio | 0.46 | 0.46 | 0.45 | 0.30 | 0.60 | 0.68 | 1.28 | 0.44 | 1.41 | 1.00 | 1.25 |
| Cash Ratio | 0.15 | 0.15 | 0.17 | 0.03 | 0.14 | 0.20 | 0.65 | 0.12 | 0.52 | 0.09 | 0.20 |
| Asset Turnover | — | 0.07 | 0.06 | 0.09 | 0.08 | 0.08 | 0.04 | 0.05 | 0.04 | 0.10 | 0.14 |
| Inventory Turnover | 9.46 | 9.46 | 13.85 | 15.22 | 7.36 | 14.25 | 9.71 | 49.34 | 50.99 | 37.07 | 48.38 |
| Days Sales Outstanding | — | 34.91 | 48.64 | 49.92 | 100.72 | 287.89 | 307.96 | 222.92 | 388.32 | 326.78 | 241.48 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 100.0% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% |
| Shares Outstanding | — | $145615 | $145600 | $145600 | $145600 | $145600 | $145600 | $144700 | $144566 | $144533 | $145133 |
Regulatory and Solvency Risk
Based on reported figures, CCM trades at a price-to-sales multiple of 0.01, a valuation level that suggests the market has largely abandoned expectations for a return to profitability or meaningful growth in the company's specialized oncology network and high-end hospital service segments in China.
The current valuation multiples appear to reflect a deep distress discount rather than a growth-oriented pricing model. Investors should monitor whether this low valuation is a temporary market overreaction or a rational response to the persistent negative operating margins and the lack of a clear path toward positive earnings.
As reported in financial statements, CCM's ROIC has remained consistently negative, hovering around -1.0% in 2025Q2, which indicates that the company is currently destroying shareholder value rather than compounding it through its heavy investments in radiotherapy equipment and specialized oncology facilities.
The inability to generate positive returns on invested capital suggests that the company's asset-heavy strategy is failing to achieve the necessary utilization rates to cover its high depreciation and operating costs. This trend warrants further investigation into whether the company's core assets are becoming obsolete or if the regulatory environment has permanently impaired their earning potential.
According to recent SEC filings, CCM's cash conversion cycle has fluctuated significantly, reaching -35 days in 2025Q2, a metric that appears to be driven more by extended payment terms to suppliers rather than operational efficiency in collecting receivables from its partner public hospitals.
The reliance on stretching accounts payable to manage liquidity may indicate strained relationships with suppliers or a lack of bargaining power in the current market. Analysts should interpret these efficiency metrics with caution, as they may mask underlying difficulties in converting service delivery into actual cash inflows.
Based on reported figures, CCM's debt-to-equity ratio has reached 2.22 as of 2025Q2, a level that highlights the company's precarious financial position as its equity base continues to erode due to persistent net losses and the absence of positive operating cash flow generation.
The company's reliance on debt to fund its capital-intensive operations appears increasingly unsustainable given the lack of interest coverage. Investors should monitor the company's ability to refinance existing obligations, as the current leverage profile leaves little room for error in a tightening regulatory and credit environment.
As indicated by the data, the market's common use of P/E ratios to evaluate CCM is fundamentally flawed, as the company's persistent negative earnings and high depreciation charges render traditional valuation metrics meaningless for assessing its true underlying value as a specialized medical infrastructure provider.
Instead of P/E, analysts should focus on asset-based valuation or adjusted EBITDA metrics that account for the specific lifecycle of radiotherapy equipment. Relying on standard healthcare multiples obscures the reality that CCM is currently an infrastructure-heavy play facing significant regulatory headwinds rather than a traditional, cash-generative hospital operator.
Includes 30+ ratios · 18 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CCM stock.
Concord Medical Services Holdings Limited's current P/E ratio is -0.1x. The historical average is 0.9x.
Concord Medical Services Holdings Limited's return on equity (ROE) is -5.4%. The historical average is -7.2%.
Based on historical data, Concord Medical Services Holdings Limited is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.
Concord Medical Services Holdings Limited has 5.6% gross margin and -52.0% operating margin.